Resource Summary Report

Generated by NIF on Aug 1, 2026

APC/Cyanine7 anti-human CD235a (Glycophorin A)

RRID:AB_2650978
Type: Antibody

Proper Citation

BioLegend Cat# 349116, RRID:AB_2650978

Antibody Information

URL: http://antibodyregistry.org/AB_2650978

Proper Citation: BioLegend Cat# 349116, RRID:AB_2650978

Target Antigen: CD235a

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Cyanine7 anti-human CD235a (Glycophorin A)

Description: This monoclonal targets CD235a

Target Organism: human

Clone ID: Clone HI264

Antibody ID: AB_2650978

Vendor: BioLegend

Catalog Number: 349116

Alternative Catalog Numbers: 349115

Record Creation Time: 20250819T235401+0000

Record Last Update: 20250820T064604+0000

Ratings and Alerts

No rating or validation information has been found for APC/Cyanine7 anti-human CD235a (Glycophorin A).

No alerts have been found for APC/Cyanine7 anti-human CD235a (Glycophorin A).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Caielli S, et al. (2024) Type I IFN drives unconventional IL-1?? secretion in lupus monocytes. Immunity, 57(11), 2497.

Vu LT, et al. (2024) Single-cell transcriptomics of the immune system in ME/CFS at baseline and following symptom provocation. Cell reports. Medicine, 5(1), 101373.

Caielli S, et al. (2021) Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell, 184(17), 4464.

Xi H, et al. (2020) A Human Skeletal Muscle Atlas Identifies the Trajectories of Stem and Progenitor Cells across Development and from Human Pluripotent Stem Cells. Cell stem cell, 27(1), 158.

Zeng Y, et al. (2019) Single-Cell RNA Sequencing Resolves Spatiotemporal Development of Pre-thymic Lymphoid Progenitors and Thymus Organogenesis in Human Embryos. Immunity, 51(5), 930.

Sade-Feldman M, et al. (2018) Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 175(4), 998.